DexCom (DXCM) Getting Somewhat Favorable Press Coverage, Report Finds
Media headlines about DexCom (NASDAQ:DXCM) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. DexCom earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave media stories about the medical device company an impact score of 46.1856314206798 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
- DexCom (DXCM) Given a $67.00 Price Target at Oppenheimer (americanbankingnews.com)
- DexCom Announces Upcoming Conference Presentations (markets.financialcontent.com)
- DexCom (DXCM) Downgraded by ValuEngine (americanbankingnews.com)
- DexCom, Inc. (DXCM) Given Consensus Rating of “Hold” by Brokerages (americanbankingnews.com)
DexCom (DXCM) traded up $0.34 during midday trading on Monday, hitting $54.69. 694,744 shares of the stock traded hands, compared to its average volume of 1,413,491. DexCom has a one year low of $42.62 and a one year high of $86.32. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $4,723.19, a price-to-earnings ratio of -95.95 and a beta of 0.21.
In related news, insider Terrance H. Gregg sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $56.86, for a total transaction of $568,600.00. Following the sale, the insider now owns 484,559 shares of the company’s stock, valued at approximately $27,552,024.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Andrew K. Balo sold 6,490 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $60.00, for a total transaction of $389,400.00. The disclosure for this sale can be found here. In the last three months, insiders sold 48,140 shares of company stock worth $2,743,281. Insiders own 1.70% of the company’s stock.
WARNING: This piece of content was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/dexcom-dxcm-getting-somewhat-favorable-press-coverage-report-finds/1862099.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.